The JAK1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

被引：0
|
作者：
La Rosee, F. [1 ,2 ]
Bremer, H. -C. [3 ]
Hochhaus, A. [4 ]
Birndt, S. [4 ]
Fellhauer, M. [5 ]
Henkes, M. [6 ]
Russo, S. G. [7 ,8 ,9 ]
La Rosee, P. [1 ,6 ]
机构：
[1] Friedrich Schiller Univ Jena, Univ Klinikum Jena, Fak Med, Jena, Germany
[2] Tech Univ Dresden, Med Fak Carl Gustav Carus, Dresden, Germany
[3] Schwarzwald Baar Klinikum, Lungenzentrum Donaueschingen, Villingen Schwenningen, Germany
[4] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany
[5] Schwarzwald Baar Klinikum, Apotheke Inst Klin Pharm, Villingen Schwenningen, Germany
[6] Schwarzwald Baar Klinikum, Klin Innere Med Hamatol Onkol Immunol Infekt & Pa, Villingen Schwenningen, Germany
[7] Schwarzwald Baar Klinikum, Klin Anasthesiol Intens Notfall & Schmerzmed, Villingen Schwenningen, Germany
[8] Univ Witten Herdecke, Fak Gesundheit, Witten, Germany
[9] Univ Gottingen, Fak Med, Gottingen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
582
引用
收藏
页码：198 / 198
页数：1
相关论文
共 50 条
  • [1] The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
    Hammersen, J.
    Birndt, S.
    Doehner, K.
    Reuken, P.
    Stallmach, A.
    Sauerbrey, P.
    La Rosee, F.
    Pfirrmann, M.
    Fabisch, C.
    Weiss, M.
    Traeger, K.
    Bremer, H.
    Russo, S.
    Illerhaus, G.
    Droemann, D.
    Schneider, S.
    La Rosee, P.
    Hochhaus, A.
    LEUKEMIA, 2023, 37 (9) : 1879 - 1886
  • [2] The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
    J. Hammersen
    S. Birndt
    K. Döhner
    P. Reuken
    A. Stallmach
    P. Sauerbrey
    F. La Rosée
    M. Pfirrmann
    C. Fabisch
    M. Weiss
    K. Träger
    H. Bremer
    S. Russo
    G. Illerhaus
    D. Drömann
    S. Schneider
    P. La Rosée
    A. Hochhaus
    Leukemia, 2023, 37 : 1879 - 1886
  • [3] The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
    F. La Rosée
    H. C. Bremer
    I. Gehrke
    A. Kehr
    A. Hochhaus
    S. Birndt
    M. Fellhauer
    M. Henkes
    B. Kumle
    S. G. Russo
    P. La Rosée
    Leukemia, 2020, 34 : 1805 - 1815
  • [4] The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
    La Rosee, F.
    Bremer, H. C.
    Gehrke, I
    Kehr, A.
    Hochhaus, A.
    Birndt, S.
    Fellhauer, M.
    Henkes, M.
    Kumle, B.
    Russo, S. G.
    La Rosee, P.
    LEUKEMIA, 2020, 34 (07) : 1805 - 1815
  • [5] Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
    Alessandro M. Vannucchi
    Benedetta Sordi
    Alessandro Morettini
    Carlo Nozzoli
    Loredana Poggesi
    Filippo Pieralli
    Alessandro Bartoloni
    Alessandro Atanasio
    Filippo Miselli
    Chiara Paoli
    Giuseppe G. Loscocco
    Andrea Fanelli
    Ombretta Para
    Andrea Berni
    Irene Tassinari
    Lorenzo Zammarchi
    Laura Maggi
    Alessio Mazzoni
    Valentina Scotti
    Giorgia Falchetti
    Danilo Malandrino
    Fabio Luise
    Giovanni Millotti
    Sara Bencini
    Manuela Capone
    Marie Pierre Piccinni
    Francesco Annunziato
    Paola Guglielmelli
    Leukemia, 2021, 35 : 1121 - 1133
  • [6] Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
    Vannucchi, Alessandro M.
    Sordi, Benedetta
    Morettini, Alessandro
    Nozzoli, Carlo
    Poggesi, Loredana
    Pieralli, Filippo
    Bartoloni, Alessandro
    Atanasio, Alessandro
    Miselli, Filippo
    Paoli, Chiara
    Loscocco, Giuseppe G.
    Fanelli, Andrea
    Para, Ombretta
    Berni, Andrea
    Tassinari, Irene
    Zammarchi, Lorenzo
    Maggi, Laura
    Mazzoni, Alessio
    Scotti, Valentina
    Falchetti, Giorgia
    Malandrino, Danilo
    Luise, Fabio
    Millotti, Giovanni
    Bencini, Sara
    Capone, Manuela
    Piccinni, Marie Pierre
    Annunziato, Francesco
    Guglielmelli, Paola
    LEUKEMIA, 2021, 35 (04) : 1121 - 1133
  • [7] Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome
    Huarte, Eduardo
    Peel, Michael T.
    Verbist, Katherine
    Fay, Brittany L.
    Bassett, Rachel
    Albeituni, Sabrin
    Nichols, Kim E.
    Smith, Paul A.
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [8] Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
    Vaddi, Kris
    Sarlis, Nicholas J.
    Gupta, Vikas
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2397 - 2407
  • [9] COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon
    Hasselbalch, H. C.
    Skov, V
    Kjaer, L.
    Ellervik, C.
    Poulsen, A.
    Poulsen, T. D.
    Nielsen, C. H.
    CYTOKINE & GROWTH FACTOR REVIEWS, 2021, 60 : 28 - 45
  • [10] Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies
    La Rosee, Felicitas
    La Rosee, Paul
    ACTA HAEMATOLOGICA, 2021, 144 (03) : 246 - 248
12345